⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25504871 | 0.80 | LMNA (0.30) | — | |
| SCHEMBL31403467 | 0.80 | — | — | |
| SCHEMBL22029169 | 0.77 | — | — | |
| SCHEMBL30101999 | 0.77 | — | — | |
| SCHEMBL31470359 | 0.77 | — | — | |
| SCHEMBL23926087 | 0.74 | GPR35 (0.31) | — | |
| SCHEMBL29409322 | 0.74 | GPR35 (0.31) | — | |
| SCHEMBL29070967 | 0.73 | — | — | |
| SCHEMBL16637138 | 0.72 | — | — | |
| SCHEMBL29409338 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116829557-B | Pentaheterocycle compound, preparation method and application thereof | 上海艾力斯医药科技股份有限公司 | 2026-05-12 | — | — | CN | disclosed |
| CN-117430540-A | Pyrrolidine compound and preparation method thereof | 上海艾力斯医药科技股份有限公司 | 2024-01-23 | — | — | CN | disclosed |
| CN-116829557-A | Pentaheterocycle compound, preparation method and application thereof | 上海艾力斯医药科技股份有限公司 | 2023-09-29 | — | — | CN | disclosed |
| EP-4135844-A1 | FUSED TRICYCLIC KRAS INHIBITORS | Incyte Corporation (US) | 2023-02-22 | — | — | EP | disclosed |
| CN-115702025-A | Fused tricyclic KRAS inhibitors | 因赛特公司 | 2023-02-14 | — | — | CN | disclosed |
| WO-2022161489-A1 | PENTAHETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海艾力斯医药科技股份有限公司 | 2022-08-04 | — | — | WO | disclosed |
| US-20210355121-A1 | FUSED TRICYCLIC KRAS INHIBITORS | INCYTE CORPORATION | 2021-11-18 | — | — | US | disclosed |
| US-20210355121-A1 | FUSED TRICYCLIC KRAS INHIBITORS | INCYTE CORPORATION | 2021-11-18 | — | — | US | disclosed |
| WO-2021211864-A1 | FUSED TRICYCLIC KRAS INHIBITORS | INCYTE CORPORATION (US) | 2021-10-21 | — | — | WO | disclosed |
| WO-2021211864-A1 | FUSED TRICYCLIC KRAS INHIBITORS | INCYTE CORPORATION (US) | 2021-10-21 | — | — | WO | disclosed |